Lilly Says Alzheimer Patients on Failed Drug Didn’t Improve

Patients testing Eli Lilly & Co.’s failed Alzheimer’s drug didn’t improve after being taken off the treatment when the company stopped the trial in August.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.